---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-24-000081"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-07-12T23:59:59+00:00"
generated_at: "2026-05-31T21:23:36.826983+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Senti Biosciences shareholders approve officer exculpation and reverse stock split authorization (range 1:5 to 1:30)

## Summary
- Stockholders approved an officer exculpation amendment limiting liability of certain officers as permitted by Delaware law; effective July 10, 2024.
- Reverse stock split approved at ratio between 1:5 and 1:30, as determined by the Board; Board may abandon the split.
- KPMG LLP ratified as independent auditor for fiscal year ending Dec 31, 2024 (30,547,655 votes for, 63,495 against).
- Officer exculpation amendment and reverse split were Proposals 2 and 3; 68.97% of outstanding shares represented at the meeting.

## SEC filing metadata
- accession: 0001854270-24-000081
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-07-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03, 5.07, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000081/0001854270-24-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000081/snti-20240710.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-24-000081
- JSON: https://secwatch.observer/filing/0001854270-24-000081.json
- Plain text: https://secwatch.observer/filing/0001854270-24-000081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.